PsACWY vaccine clinical trials
How each study uses PsACWY vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Mencevax ACWY
- 5
Studies by the year they started
6 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Vaccines (1)
Studies
Open first, then newest update. How each study uses PsACWY vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mCompletedPhase 3GlaxoSmithKlineNCT00136604Written as Mencevax ACWY
- Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in ChildrenCompletedPhase 3GlaxoSmithKlineNCT00228917Written as Mencevax-ACWY
- Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 YearsCompletedPhase 4GlaxoSmithKlineNCT00290329Written as Mencevax ACWY
- Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedPhase 3GlaxoSmithKlineNCT00291343Written as Mencevax™ ACWY
- Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate VaccineCompletedPhase 2GlaxoSmithKlineNCT00126984Written as Mencevax ACWY
- Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 YrsCompletedPhase 4GlaxoSmithKlineNCT00227422Written as Mencevax ACWY
Given beside what is tested · 1 — PsACWY vaccine is usual care or a partner of the new treatment
As the comparator · 5 — what is tested is compared with PsACWY vaccine
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year OldsCompletedPhase 3GlaxoSmithKlineNCT01154088Written as Mencevax ACWY
- Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate VaccineCompletedPhase 2GlaxoSmithKlineNCT00356369Written as Mencevax™ ACWY
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old SubjectsCompletedPhase 3GlaxoSmithKlineNCT00464815Written as Mencevax™ ACWY
- Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612CompletedPhase 2GlaxoSmithKlineNCT00427908Written as Mencevax™ ACWY
- Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612CompletedPhase 2GlaxoSmithKlineNCT00390143Written as Mencevax™ ACWY